3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Recurrence
1
Interventions
pembrolizumab
30
Cisplatin
20
Carboplatin
20
Paclitaxel
18
Dexamethasone
15
Pemetrexed
13
Nivolumab
13
Ipilimumab
12
Fluorouracil
11
Cyclophosphamide
11
Gemcitabine
10
Trastuzumab
9
Docetaxel
9
Cytarabine
9
daratumumab
8
atezolizumab
8
Rituximab
8
Capecitabine
8
Lenalidomide
7
Doxorubicin
7
zanubrutinib
6
Prednisone
6
Daunorubicin
6
Bortezomib
6
venetoclax
5
trametinib
5
nilotinib
5
ibrutinib
5
fludarabine
5
dabrafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Has announcements
×
selinexor
×
Clear all
NCT03110562
2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3
Completed
402 enrolled
22 charts
1 FDA
NCT02336815
2023-01-26
STORM
Karyopharm Therapeutics Inc
Phase 2
Completed
202 enrolled
30 charts
1 FDA